Critical Reviews™ in Therapeutic Drug Carrier Systems

ISSN for PRINT: 0743-4863

For Online Access

Best Paper Award Selection - Editorial Board Site

2006, Volume23

Issue 5

96 pages

Issue price - $174.00

Jayant J. Khandare
Department of Pharmaceutics, Rutgers, The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, NJ 08854, USA

Dr. Tamara Minko
Associate Professor, Dept. of Pharmaceutics, School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854-8020

Antibodies and peptides play a variety of roles in cancer therapy: monoclonal antibodies (mAbs) and peptides are directly used in anticancer therapy and also as targeting moieties. More than 10 mAbs, either unconjugated or in immunoconjugate forms have been approved for use in oncology. Various peptides, tumor necrosis factors (TNFs), and cell surface-targeted peptides have been identified using phage-display libraries. In combination with standard chemotherapeutic agents, mAbs and peptides can significantly increase the toxicity of anticancer drugs to tumors and reduce their adverse side effects on normal tissues. The present review summarizes some major applications of antibodies and peptides in cancer therapy.

Download article, 401-436 pages

Article price - $70.00

<< Previous article